AC Immune: five neurodegeneration shots before the 2027 cash clock rings
AC Immune has partner-backed Alzheimer's programs, a Parkinson's active immunotherapy readout, a new NLRP3 Phase 1 asset, and CHF 74.8 million of Q1 2026 cash resources. The hard question is whether 2026 milestones can turn platform promise into partner commit
Open